Coronavirus Disease 2019 (COVID-19) is a disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. It was first isolated in Wuhan, China in December 2019 and then rapidly spread to the rest of the world posing a severe threat to global health. Many therapeutics have been investigated for the treatment of this disease with inconclusive outcomes. Protease inhibitors are one of the proposed agents, but their use is limited to their significant drug interactions and side effects. The aim of this study is to compare the efficacy and safety outcomes of Darunavir/Cobicistat versus Lopinavir /Ritonavir in the treatment of patients with COVID-19 pneumonia in Qatar.
Drug: Darunavir/Cobicistat
Darunavir/Cobicistat (800mg/150mg) 1 tablet PO once daily
Drug: Lopinavir/Ritonavir
Lopinavir/Ritonavir (200mg/50mg) 2 tablets PO twice daily
Inclusion Criteria:
- Adult patients ≥18 years of age
- Laboratory confirmed 2019-nCoV infection as determined by the PCR of the
nasopharyngeal/oropharyngeal swab.
- Radiologically confirmed pneumonia (Based on the chest x-ray or CT scan imaging).
- Have received either Darunavir/Cobicistat or Lopinavir/Ritonavir as part of the
treatment regimen for COVID-19 pneumonia
Exclusion Criteria:
- No exclusion criteria will be applied
Hamad Medical Corporation
Doha, Qatar
Dr. Eman Elmekaty, PharmD, Principal Investigator
Hamad Medical Corporation